SecreFlo(TM) Home
IndicationsNews and EventsPublicationsOrdering Information

HomeContact UsPrescribing Information
Recent Publications
The following publications describe the experiences of various physicians using SecreFloTM for its FDA approved indications:


NEW - Facilitation of Pancreatic Duct Cannulation Using a New Synthetic Porcine Secretin
AMERICAN JOURNAL OF GASTROENTEROLOGY 2002. Vol. 97, No. 9. 2279-81.
Benedict M. Devereaux, Glen A. Lehman MD, Seymour Fein, Ph.D., Susan Phillips, RN., Evan Fogel, MD. and Stuart Sherman, MD.

Synthetic Porcine Secretin is highly accurate in pancreatic function testing in individuals with chronic pancreatitis.
PANCREAS. Vol 21, No.3, pp262-265.
Lehel Somogyi MD, Phillip Toskes, MD, Miriam Cintron.

A Randomized Controlled Crossover Study Comparing Synthetic Porcine and Human Secretins with Biologically Derived Porcine Secretin to Diagnose Zollinger-Ellison Syndrome
ALIMENTARY PHARMACOLOGICAL THEORY. 2001, May 15 (5) pp669-676.
David Metz, M.D., Maria Buchanan, RN.

Chronic Pancreatitis
CURRENT OPINION IN GASTROENTEROLOGY. 2002. Vol. 18, pp558-562.
Peter Draganov, M.D., Philip Toskes M.D.
© Copyright 2002, Repligen Corporation. All rights reserved.

Disclaimer for U.S. Physycians — All information appearing on this site is intended only for healthcare professionals practicing in the United States to provide knowledge and information about SecreFloTM, secretin for injection, and its FDA-approved indications. Repligen Corporation will endeavor to include accurate and up-to-date information on this site, but makes no warranties or representations as to the accuracy or completeness of the contents of this site or of any site linked to this site. For more detailed information regarding SecreFloTM dosing or test administration, please refer to the current prescribing information.